Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Biora Therapeutics, Inc.

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Reverse Stock Split
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces $9.75 Million Direct Offering
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.